Drepaglobe

N/A

Report date: 2023/04/07 13:58:00

Base Information

Drug NameDrepaglobe

Drug Alias Nameautologous human CD34+ hematopoietic stem and progenitor cells

ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vectorCell and gene therapy > Cell therapy > Stem cell therapy > Hematopoietic stem cells therapy

Mechanisms of ActionCell replacements

TargetsNot applicable

Therapy Area/IndicationsAnemia, Sickle Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryFrance

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesAssistance Publique Hopitaux De Paris

China Registration ClassN/A

Develop Information

Active CompaniesAssistance Publique Hopitaux De Paris

Inactive CompaniesN/A

Active IndicationsAnemia, Sickle Cell

Inactive IndicationsN/A

Other Information

ATC CodeN/A